Drugmakers slash prices in China to get on reimbursement list
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY) Ahead of Conference Call
December 2, 2019 7:00 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $143.00 price target on Eli Lilly (NYSE: LLY) ahead of a conference call to discuss Alzheimers disease treatment landscape and what to expect at CTAD.
For an analyst ratings summary and... More
